Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

HS235

Phase 1Biologic

HS235 is one of 75 biologic programs targeting Pulmonary Hypertension. It is currently in Phase 1.

2

Indications

3

Total Trials

2

Active Trials

74

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary HypertensionRecruiting

Pulmonary Arterial HypertensionRecruiting

Pulmonary HypertensionPhase 1

Recruiting

Pulmonary Arterial HypertensionPhase 1

Recruiting

Competition

Competitive Landscape

53 competitors in Pulmonary Hypertension

#DrugCompanyPhaseTrials

Viagra

VViatris Specialty LLC

Letairis

Tracleer

Johnson & Johnson

Cialis

Adempas

Opsumit

Johnson & Johnson

Remodulin

United Therapeutics

Primacor

Levitra

Uptravi

Johnson & Johnson

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Pulmonary Arterial Hypertension

NCT07143448

Q1 2030

PreclinicalRecruiting

Pulmonary Hypertension

NCT07123779

Clinical

Trials by Indication[1]

Overweight1 trial

Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics in Overweight/Obese Healthy Subjects

Completed·335Pharma Inc·Phase 1·NCT06714825·39 enrolled

Pulmonary Arterial Hypertension1 trial

Phase 1b/2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HS235 Added to Background Treatment in Adults With PAH

Recruiting·335Pharma Inc·Preclinical·NCT07143448·90 enrolled

Pulmonary Hypertension1 trial

Phase 1b/2, Multicenter, Double-Blind, Placebo-Controlled, Multiple Dose Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS235 in Obese Participants With Pulmonary Hypertension and HFpEF

Recruiting·335Pharma Inc·Preclinical·NCT07123779·126 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for HS235. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HS235 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HS235. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — 35Pharma Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: 335Pharma Inc

Related News